Takes one to B1a: Dismantling the origin of mantle cell lymphoma
Open Access
- 16 September 2021
- journal article
- editorial
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 218 (10)
- https://doi.org/10.1084/jem.20211482
Abstract
Therapeutic discovery for mantle cell lymphoma (MCL) has been hindered by a lack of preclinical mouse models that recapitulate human disease. In this issue, Pieters and colleagues (2021. J. Exp. Med.https://doi.org/10.1084/jem.20202280) establish a novel mouse model of MCL driven by overexpression of cyclin D2 and identify fetal-derived B1a cells as putative cell of origin for MCL.Funding Information
- Pew Charitable Trusts
- Hellman Fellows Award
- National Heart, Lung, and Blood Institute (R01HL147081, K01 HL130753)
This publication has 13 references indexed in Scilit:
- Many layers of embryonic hematopoiesis: new insights into B-cell ontogeny and the origin of hematopoietic stem cellsExperimental Hematology, 2017
- Nur77 Is Upregulated in B-1a Cells by Chronic Self-Antigen Stimulation and Limits Generation of Natural IgM Plasma CellsImmunoHorizons, 2017
- B-cell receptor–driven MALT1 activity regulates MYC signaling in mantle cell lymphomaBlood, 2017
- B-1 Cell Heterogeneity and the Regulation of Natural and Antigen-Induced IgM ProductionFrontiers in Immunology, 2016
- Distinct mechanisms define murine B cell lineage immunoglobulin heavy chain (IgH) repertoireseLife, 2015
- Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionTherapeutic Advances in Hematology, 2015
- The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphomaBlood, 2013
- CCND2 rearrangements are the most frequent genetic events in cyclin D1− mantle cell lymphomaBlood, 2013
- Cyclin D as a therapeutic target in cancerNature Reviews Cancer, 2011
- Differential Requirement for Malt1 in T and B Cell Antigen Receptor SignalingImmunity, 2003